

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196)

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues were identified during draft scope consultation. No scoping workshop was held for this topic. No issues had been previously identified in TA196.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Not applicable – no potential equality issues have been identified.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable – no potential equality issues have been identified

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equalities issues were

identified during the scoping process.

Approved by Associate Director (name): Helen Knight

Date: 26/11/2013